MORINDA'S DIRECTOR OF RESEARCH HELPS PUBLISH NEW IRIDOID STUDY
There’s more evidence that iridoids reduce AGE levels, thanks to Morinda’s Brett
Morinda has always been on the cutting edge of research, and that has continued
with a recent study linking iridoid consumption to reduced AGE (advanced glycation end-product) levels. The study (“Antiglycation Activity of Iridoids and Their Food Sources”), which was
published in the International Journal of Food Science, was conducted in part by Dr. Brett
West, Morinda’s Director of Research.
The published study, which found that consuming dietary sources of iridoids results in reduced AGE
levels, was actually based off two different studies. One was a human pilot study in which 34
participants drank between 60 and 240 mL of TruAge Max each day for eight weeks. Max contains five sources of iridoids: noni, Cornelian cherry, blueberry,
cranberry and olive leaf extract.
The participants had their AGE levels recorded with the TruAge Scanner. After the eight-week trial, each participant’s TruAge had been lowered by an average of five years.
The other study was a cross-sectional population study in which 3,913 people (some which consume
iridoids, some which don’t) had their AGE levels measured. On average, those who consumed iridoids
had skin AGE levels that were associated with people who were 2.07 years younger than themselves.
However, those that didn’t consume iridoids had AGE levels that were not significantly different
from those of previously studied general healthy populations.
“One of the important takeaways is that data from almost 4,000 people reveal an association between
increased daily iridoid intake and reduced AGE levels,” said West, who also serves as a member of
the AGE Foundation’s advisory board. “This appears to confirm our conclusions
from in vitro experiments and an eight-week human intervention study.”
AGEs are receiving more and more attention from the public and the media, but for years now Morinda
has been finding ways to help reduce AGE levels and educate people about how these harmful
compounds prematurely age our bodies and lead to various health problems.
In fact, in 2009 Morinda researchers were the first to discover that much of the benefit of noni
comes from chemical compounds known as iridoids. This important discovery is just another example
of Morinda’s innovative nature, with another example being the fact that it was the first company
to harvest, source and distribute a noni-based product to the consumer market.
Morinda has even spent more than $125 million on research and development, and has published human
clinical trials (several of which were featured in the Physician’s Desk Reference). In addition,
the company boasts a state-of-the-art, multi-million dollar laboratory dedicated to product